CRB091 / Cancer Research and Biotechnology AG - LARVOL DELTA

A novel treatment CRB091 effectively reduces cancer cell proliferation in triple-negative breast cancer (TNBC) (Canada Newswire) - "CRB091, a novel drug candidate developed by Cancer Research and Biotechnology AG (CRB), has shown significant promise in reducing cancer cell proliferation in difficult-to-treat cancers such as colorectal and triple-negative breast cancers. The preclinical studies conducted by an independent research laboratory in the UK demonstrated a significant reduction in human cancer cell proliferation in vitro, with a synergistic effect between the product's single ingredients....CRB091's active molecules have been proven safe for human use, and CRB anticipates initiating the first-in-human clinical trials in the US in 12 months. The FDA's Pre-Investigational New Drug (Pre-IND) application advice is scheduled in Q3 2023, with the IND filing in Q3 2024."

FDA event • IND • Preclinical • Breast Cancer • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer